Bring­ing their ge­net­i­cal­ly mod­i­fied gam­ma delta T cells to Nas­daq, IN8bio files for $86M IPO

The biotech IPO pa­rade con­tin­ues march­ing for­ward as 2020 turns to­ward the fourth quar­ter.

IN8bio, a New York-based com­pa­ny fo­cused on ge­net­i­cal­ly mod­i­fied gam­ma delta T cell ther­a­pies, filed to go pub­lic Fri­day seek­ing an $86 mil­lion raise. The com­pa­ny has two clin­i­cal-stage can­di­dates be­ing stud­ied in glioblas­toma and leukemia, re­spec­tive­ly.

By any stretch of the imag­i­na­tion, 2020 has al­ready been a huge year for biotech, and nowhere does it ap­pear more ob­vi­ous than the vast amounts of com­pa­nies hit­ting the pub­lic mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER